Compare SNV & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNV | CYTK |
|---|---|---|
| Founded | 1888 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 8.0B |
| IPO Year | N/A | 2004 |
| Metric | SNV | CYTK |
|---|---|---|
| Price | $52.42 | $62.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 15 |
| Target Price | $57.93 | ★ $77.87 |
| AVG Volume (30 Days) | 795.1K | ★ 1.8M |
| Earning Date | 01-21-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | ★ 143.15 | N/A |
| EPS | ★ 5.35 | N/A |
| Revenue | ★ $2,291,796,000.00 | $87,211,000.00 |
| Revenue This Year | $30.53 | $361.33 |
| Revenue Next Year | $4.80 | $65.14 |
| P/E Ratio | $9.77 | ★ N/A |
| Revenue Growth | 31.11 | ★ 2609.26 |
| 52 Week Low | $35.94 | $29.31 |
| 52 Week High | $61.06 | $69.33 |
| Indicator | SNV | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 66.43 | 49.62 |
| Support Level | $51.98 | $59.37 |
| Resistance Level | $53.47 | $63.80 |
| Average True Range (ATR) | 1.02 | 2.56 |
| MACD | 0.09 | -0.44 |
| Stochastic Oscillator | 75.02 | 42.46 |
Synovus Financial Corp provides commercial and consumer banking in addition to a full suite of specialized products & services such as private banking, treasury management, wealth management, mortgage services, premium finance, asset-based lending, structured lending, capital markets, & international banking to clients through the wholly-owned subsidiary bank, Synovus Bank, and other offices in Alabama, Florida, Georgia, South Carolina, and Tennessee. It has four segments Wholesale Banking, Community Banking, Consumer Banking, and Financial Management Services, out of which the majority is from the Wholesale banking segment.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.